DrugPatentWatch Database Preview
VIIBRYD Drug Profile
When do Viibryd patents expire, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Allergan Sales Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
Summary for VIIBRYD
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 60 |
| Clinical Trials: | 16 |
| Patent Applications: | 35 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIIBRYD |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| DailyMed Link: | VIIBRYD at DailyMed |
Generic Entry Opportunity Date for VIIBRYD
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Medical Subject Heading (MeSH) Categories for VIIBRYD
Synonyms for VIIBRYD
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 163521-08-2 |
| 2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) |
| 2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride |
| 2794AH |
| 4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride |
| 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride |
| 5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride |
| 521V128 |
| AB0000947 |
| AC-25885 |
| AC1OCFA0 |
| AK161007 |
| AKOS024464039 |
| AN-5344 |
| API0009252 |
| AX8294006 |
| C26H27N5O2.ClH |
| CCG-213313 |
| CHEBI:70705 |
| CHEMBL1615374 |
| CS-0549 |
| D09699 |
| EBD2199528 |
| EMD 68 843 |
| EMD 68843 |
| EMD-68-843 |
| EMD-68843 |
| EMD68843 |
| HE069874 |
| HY-14261 |
| J-525160 |
| KB-81444 |
| KS-00000SKE |
| LS-34922 |
| MFCD00940014 |
| MolPort-028-744-909 |
| RL02096 |
| RL02097 |
| RPZBRGFNBNQSOP-UHFFFAOYSA-N |
| s4259 |
| SB 659746A |
| SB-659746-A |
| SB-659746A |
| SB659746-A |
| SB659746A |
| SCHEMBL867358 |
| ST24050347 |
| U8HTX2GK8J |
| UNII-U8HTX2GK8J |
| Viibryd (TN) |
| Vilazodone (Hydrochloride) |
| Vilazodone HCl |
| Vilazodone hydrochloride |
| Vilazodone hydrochloride (USAN) |
| Vilazodone hydrochloride [USAN] |
| Vilazodone Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Vilazodone hydrochloride, >=98% (HPLC) |
| vilazodone monohydrochloride |
| Vilazodonei |
US Patents and Regulatory Information for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for VIIBRYD
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for VIIBRYD
| Country | Document Number | Estimated Expiration |
|---|---|---|
| New Zealand | 530642 | ➤ Sign Up |
| Australia | 7424494 | ➤ Sign Up |
| Czech Republic | 20040026 | ➤ Sign Up |
| Denmark | 1397357 | ➤ Sign Up |
| Slovakia | 162004 | ➤ Sign Up |
| European Patent Office | 0648767 | ➤ Sign Up |
| Poland | 208708 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
